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Abstract
Thevalueof adjusting thediffusingcapacity for thelungvolumehasbeendemonstratedin a largenumberofpatientswith
other lung diseases but has not been validated in patients with cystic fibrosis (CF).Pulmonary function test results on a
cohortof 52 adult CF patientswere analyzed to determinewhether the diffusing capacityof carbonmonoxide by single
breathmethod (DLCOSB), when adjusted for alveolar volume (VA%), correlatedwiththe severityof pulmonary dysfunc-
tion. The DLCOSB remained within the reference range except in those with severe lung impairment (61.88715.48%).
DLCOSBhas a significant (Po0.05) positive correlation (0.70,0.67,0.48,0.69, and 0.31, respectively)withmeasuresof airflow
limitation (FVC%,FEV1%,FEV1/FVC%,MVV%, and sGaw) and negative correlation (0.36 and0.21, respectively) with
measures of air trapping (RV% and RV/TLC%). DLCOSB/VA remained above100% of predicted despite worsening lung
disease anddidnotcorrelatewithothermeasuresof lung function.Onthe otherhand, theDLCOSB andDLCOSB/VA,when
adjusted for VA%, decreased andwere significantly correlatedwithworsening airflow limitation and, to a lesser extent,
air trapping.Therelativelypreserved adjusted DLCOSB and DLCOSB/VAvalues in CF patientsup untillate in its coursemay
beexplainedthepredominant airwayinvolvement,minimallossof alveolar-capillaryunits, andenhanced V/Qrelationship
due to claustration in CF.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1487, available online athttp://www.sciencedirect.com
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The conventional single breath method originally de-
scribed by Krogh (1) is themost widely usedmethod for
measuringdi¡using capacity (DLCOSB) invarious pulmon-
ary disorders. Factors that can alter the di¡using capa-
city have been reviewed by Cotton et al. (2).Meanwhile,
there have been con£icting reports on the behavior of
DLCOSB in cystic ¢brosis (CF). After Keens et al. (3)
found that the DLCOSB was elevated in asthmatic sub-
jects andpatientswith CF, they proposed that the eleva-
tion is partly due to the maximal inspiration against
obstructed airways causing abnormally negative in-Received 23 April 2002, accepted in revised form 20 November 2002
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Fax: +1314 577 8859; E-mail: jrde2068@yahoo.comtrathoracic pressures, thereby increasing the pulmonary
capillary blood volume.O’ Brodovich and colleagues ob-
served that10 patients with CF had normal DLCOSB and
proposed that hypoxic pulmonary vasoconstriction
tends to recruit the pulmonary vascular bed at the
apexes (4). In contrast, Russell et al. (5) reported that
not only was DLCOSB decreased in 8 patients with CF, it
also had thebest correlationwith othermeasures of pul-
monary function. Although Russell’s cohort had a low
mean DLCOSB (6878.5%), 7 of 8 patients had a DLCOSB/
VA (ratio of di¡using capacity to alveolar volume, also re-
ferred to as the carbonmonoxide transfer coe⁄cient, or
KCO) that was above 75% of predicted normal
(mean=92.575.5%). Russell’s group proposed that the
reduction of DLCOSB in the face of a normal DLCOSB/VA
may re£ect a decrease in accessible alveolar volume
rather than impaired gas transfer. However, because of
the small number of CF patients studied in this cohort,
recommendations regarding the usefulness of DLCOSB/
DIFFUSINGCAPACITYINFIBROSIS 607VA in assessing the severity of CF lung disease cannot be
made.
Johnson described the importance of adjusting both
DLCO and DLCO/VA for alveolar volume (VA%) in healthy
subjects as well as patients with respiratory disorders
such as asthma, emphysema, extrapulmonary lung dis-
ease, and sarcoidosis (6).There has been no published re-
port on the clinical usefulness of these adjustments of
DLCOSB and DLCOSB/VA for lung volume in adult CF pa-
tients. Thus, we reviewed the pulmonary function test
(PFT) results on a cohort of adult CF patients to deter-
mine whether DLCOSB and DLCOSB/VA, adjusted for al-
veolar volume correlated with the severity of
pulmonary dysfunction.
METHODS
Study population
All the adult CF patients with complete PFT followed at
the adult CF clinic of a university hospital were included
in the analysis. The diagnosis of CF in this cohort was
based upon the documented presence of phenotypical
clinical features (chronic sinopulmonary disease, gastro-
intestinal and nutritional abnormalities) and laboratory
evidence of cystic ¢brosis transmembrane conductance
regulator dysfunction (CFTR) gene (elevated sweat
chloride or mutation of the CFTR gene on both alleles)
(7). All of the patients were enrolled in the Cystic Fibro-
sis Foundation Registry.
Data collection
Analysis of the PFTresults on all the patients attending
the adult CF clinic of a university hospital were exam-
ined, retrospectively. Results of the most recent PFT,
which included spirometry, lung volumes, and di¡using
capacities were retrieved from the hospital computer
system or the medical record of the hospital or clinic.
Eachpatient’s age at the time of the PFTwas determined.
The PFTon each patientwas performed at an accredited
university hospital PFT laboratory. Spirometry was per-
formed with either a £ow-based system (Sensormedics
2200; Sensormedics Corporation, Yorba Linda, CA,
U.S.A.) or a volume-based system (Collins GS, Collins
Inc., Braintree, MA, U.S.A.). The PFT maneuvers were
recorded according to the AmericanThoracic Society’s
(ATS) criteria for acceptability and reproducibility (8).
Functional residual capacity was measured primarily by
use of constant volume plethysmography (Collins Body
Plethysmograph, Collins, Inc.). In a few instances when
plethysmography was not performed, lung volumes de-
rived from by helium dilution was substituted. DLCOSB
weremeasuredby use of the single breath technique fol-
lowing the guidelines of the ATS (9). Pre-bronchodilator
PFT variables were collected and included forced vitalcapacity (FVC) in liters and as percent of predicted;
forced expiratory volume in 1s (FEV1) in liters and as
percent of predicted; the FEV1/FVC ratio; maximum
voluntary ventilation (MVV) as percent of predicted;
total lung capacity (TLC) in liters and as percent of pre-
dicted; residual volume (RV) as percent of predicted; RV/
TLC ratio; airway resistance (Raw) in cm H2O/l s; and
speci¢c airway conductance (sGaw) in l2/s cm H2O;
DLCOSB in ml/min/mmHg and as percent of predicted;
the alveolar volume measured during the DLCOSB man-
euver as percent of predicted (VA%); theDLCOSB/VA, also
known as the carbon monoxide transfer coe⁄cient
(KCO); and the VA/TLC ratio (10^12). The DLCOSB was
calculated following the formula recommended by the
ATS and using the VA measured during the DLCO single
breath maneuver (9). The predicted DLCOSB was calcu-
lated using Gaensler andWright’s equations:
DLCOSB ¼ ð0:250 heightÞ  ð0:177 ageÞ þ 19:93
formales;
DLCOSB ¼ ð0:284 heightÞ  ð0:177 ageÞ þ 19:93
forfemales
and
DLCOSB ¼ ð0:693 heightÞ  20:13
forchildren
using inches for height and years for age, respectively
(12).
The predictedDLCOSB/VA is calculatedusing the equa-
tion: predicted DLCOSB/VA=(predicted DLCOSB)/(pre-
dicted TLC ^ VD or anatomic dead space). To adjust the
predicted DLCOSB for alveolar volume (VA%) as recom-
mendedby Johnson (6), the predictedDLCOSBwasmulti-
pliedby the factor: [0.58+0.42(VA/predictedVA at TLC)].
And to adjust the predicted DLCOSB/VA for alveolar vo-
lume, thepredictedDLCOSB/VAwasmultipliedby the fac-
tor: [0.42+0.58/(VA/predicted VA at TLC)].
If arterial blood gases were obtained as part of the
PFT, the following parameters were also collected: pH,
partial pressure of oxygen in arterial blood (PaO2), par-
tial pressure of carbon dioxide in arterial blood (PaCO2),
arterial oxygen saturation by co-oximetry (O2Hb), car-
boxyhemoglobin (COHb), methemoglobin (MetHb), and
hemoglobin level (Hb).
Statistical analysis
The patients were classi¢ed based on the severity of CF
pulmonary diseaseusing the FEV1 (% of predicted) as fol-
lows: normal Z80%; mild=60^79%; moderate=40^
59%; and severeo40%.The correlation coe⁄cients be-
tween DLCOSB and DLCOSB/VA, both unadjusted and ad-
justed for VA%, respectively, and the rest of the
pulmonary function parameters were determined. The
P-values of the correlation coe⁄cients were also
608 RESPIRATORYMEDICINEdetermined by calculating the t-statistic. A P-value of
o0.05 was considered signi¢cant.
RESULTS
Patient characteristics
Pulmonary function testresultswere available in 52adult
CF patients.Therewere 27males and 25 females and the
mean agewas 28.2477.79 years.
Arterial blood gases
The mean values of room air arterial blood gases
in 14 patients were pH=7.4270.02, PaCO2=40.337
4.29mmHg,PaO2=76.00711.34mmHg,O2Hb%=92.517
2.42%, COHb=1.5171.64%, MetHb=0.3170.27%, and
Hb=13.3971.38g/dl.
Single breath carbonmonoxide test results
(Table1)
Themean DLCOSB decreasedwithworsening severity of
CF lung disease and droppedbelow 80% predicted in the
group with severe lung impairment. The DLCOSB/VA (or
KCO) was consistently higher than the DLCOSB in each
category of severity of pulmonary disease and was con-
sistently above 100% in all groups despite worsening se-
verity of pulmonary disease. Meanwhile both the mean
DLCOSB and DLCOSB/VA, when adjusted for VA% and ad-
justed for VA% as per Johnson’s equations, behaved simi-
larly to the unadjusted DLCOSB and decreased with
worsening lung function. However, both the adjusted
DLCOSB and DLCOSB/VA values were consistently higher
than theunadjustedDLCOSB andonly fellbelow 80%pre-
dicted in the groupwith severe CF lung disease.TheVA%
estimated during the single breath maneuver decreased
withworsening air£ow limitation.TheVA/TLC%, an indi-
cator of the extent of equilibration of inhaled lung vo-
lume, also paralleled air£ow limitation, and was
diminished especially in the groups with moderate-to-TABLE 1. Single breath di¡using capacity results of adult cystic
based onthe FEV1and their correlation (r) with DLCO
SB and DLCO
PFT parameter Normal (n=9) Mil
DLCO (ml/min/mmHg) 32.8574.29 24.3
DLCO (%) 103.78722.52 88.7
DLCO/VA (%) 132.02726.50 112.4
Estimated VA (%) 88.0779.75 67.8
VA/TLC (%) 88.67712.51 79.4
DLCOadj forVA% 135.02726.61 105.7
DLCO/VA adj forVA% 121.82724.48 94.2severe CF-related airway obstruction. Thus, while the
DLCOSB, both unadjusted and adjusted for alveolar vo-
lume, and the DLCOSB/VA adjusted for alveolar volume,
decreased with worsening CF lung disease, particularly
in thosewith advanced air£ow limitation, the unadjusted
DLCOSB/VA remained normal or supranormal despite
worsening pulmonary dysfunction due to CF.
Spirometry and results (Table 2)
Measures of air£ow limitation (FVC, FEV1, FEV1/FVC%,
MVV%) decreased with worsening severity of lung func-
tion as expected. The mean DLCOSB%, both unadjusted
and adjusted for VA%, was signi¢cantly correlated with
measures of air£ow limitation, namely FEV1, FVC, and
FEV1/FVC%, and MVV%. Except for a weak correlation
with MVV%, the unadjusted DLCO/VA had no signi¢cant
correlation with spirometric measures of air£ow limita-
tion.However, theDLCO/VA,when adjusted forVA%, cor-
related well with measures of air£ow limitation (FEV1,
FVC, and FEV1/FVC%, and MVV%).
Body plethysmography (Table 3)
Air trapping (mRVandmRV/TLCratio) became evident in
the groups with moderate-to-severe lung impairment.
Hyperin£ation (mTLC)was notobservedevenwithwor-
sening severity of lung function. Airwayresistance (Raw)
increased while speci¢c airway conductance (sGaw) de-
creasedwithworseningCF lungdisease as expected.The
unadjusted DLCOSB% hadweak positive correlationwith
hyperin£ation (TLC%) and a weak negative correlation
with air trapping (RV% and RV/TLC%). The unadjusted
DLCOSB/VA did not correlate with any of the body
plethysmographic variables. Adjusting the DLCOSB and
DLCOSB/VA forVA% resultedonly in a signi¢cantbutweak
positive correlationwith RV%.TheDLCOSB% had a signif-
icant but weak negative correlation with Raw and posi-
tive correlation sGaw, respectively. On the other hand,
the DLCOSB adjusted for VA%, and the DLCOSB/VA, ad-
justed and unadjusted for VA%, had nomeaningful corre-¢brosis patients classi¢ed according to severityof lung disease
SB/VA, adjusted andunadjusted forVA% predicted.
d (n=10) Moderate (n=8) Severe (n=25)
275.72 19.1373.08 18.8676.39
0718.63 80.25711.00 61.88715.48
7724.95 116.00720.26 112.24722.75
6728.74 69.2379.12 46.95725.96
1730.33 67.7677.30 48.76727.59
8740.20 98.51724.05 79.78716.36
6717.30 91.14712.98 78.51715.91
TABLE 2. Spirometryresults of adultcystic ¢brosis patients classi¢ed according to severityof lungdisease based onthe FEV1
and their correlation (r) with DLCOSB and DLCOSB/VA, adjusted andunadjusted forVA% predicted
PFT parameter Normal
(n=9)
Mild
(n=10)
Moderate
(n=8)
Severe
(n=25)
r with
DLCO%
rwith
DLCO/VA
rwith
DLCO for
VA% pred
rwith
DLCO/VA
forVA%
pred
FVC (l) 4.5370.64 3.7570.93 2.6170.37 2.2870.65 0.60* 0.03 0.43* 0.46*
FVC (%) 95.3377.97 79.8078.16 68.8879.26 50.6479.10 0.70* 0.03 0.06* 0.56*
FEV1 (l) 3.4670.72 2.7470.57 1.6170.25 1.1070.30 0.63* 0.05 0.45* 0.51*
FEV1 (%) 91.3379.86 73.775.54 51.1374.94 30.9676.55 0.67* 0.10 0.53* 0.55*
FEV1/FVC (%) 76.22710.58 74.3078.72 62.0075.93 49.60712.38 0.48* 0.13 0.30* 0.36*
MVV (%) 105.78720.77 91.90710.93 59.6376.00 39.28712.45 0.69* 0.23* 0.55* 0.59*
TABLE 3. Bodyplethysmographyresultsof adultcystic ¢brosispatientsclassi¢edaccording to severityof lungdiseasebasedon
the FEV1and their correlation (r) with DLCO
SB and DLCOSB/VA, adjusted andunadjusted forVA% predicted.
PFT parameter Normal
(n=9)
Mild
(n=10)
Moderate
(n=8)
Severe
(n=25)
rwith
DLCO
rwith
DLCO/VA
rwith
DLCO
adjusted
for VA%
pred
rwith
DLCO/VA
adjusted
for VA%
pred
TLC (l) 6.4370.95 5.6371.40 5.3370.61 5.7871.49 0.20 0.07 0.10 0.11
TLC (%) 102.88710.01 88713.14 104.13712.23 94.16716.23 0.27* 0.02 0.21 0.10
RV (%) 117.63726.57 107.60734.85 186.75743.01 199.21765.33 0.36* 0.10 0.30* 0.32*
RV/TLC (%) 30.1378.53 37.60721.13 46.0076.55 67.32750.43 0.21 0.08 0.18 0.13
Raw (cmH2O/l
*s) 2.0871.22 1.9370.49 3.1570.60 3.4871.68 0.25* 0.18 0.12 0.14
sGaw (l/s cmH2O) 0.1970.11 0.1770.06 0.0970.02 0.0770.03 0.31
* 0.01 0.16 0.24
DIFFUSINGCAPACITYINFIBROSIS 609lation with Raw or sGaw. Hence, the di¡using capacity
measurementshave, atbest, only weakcorrelationswith
the body plethysomographic-derived variables such as
lung volumes and airway conductance/resistance.
DISCUSSION
Pulmonary function testing is very useful in monitoring
the status of lung function in CF patients. Traditionally,
the severity of most obstructive lung disease has been
classi¢ed based on the FEV1 (13). Among children with
CF, the RV/TLC ratio and the FEF25^75% (forced expira-
tory £ow rate over themiddle 50% of the FVC), but not
the FEV1, have been demonstrated to be themost sensi-
tive tests for airway obstruction (14,15). However as the
CF patient reaches adulthood, FEV1has been found to be
the best independent predictor of survival (16) and has
been a referral criterion for lung transplantation (17).
The spirometric and body plethysmographic ¢ndings in
our CF cohort simply con¢rmedwell-known pulmonary
function abnormalities in adult CF and includeworsening
air£ow limitation (kFVC, kFEV1/FVC, kMVV%, ksGaw,and mRaw) and air trapping (mRV and mRV//TLC) with
progressive CF lung disease.These PFT derangements in
CF result from progressive obstructive ventilatory im-
pairment due to bronchiectasis. Proposed pathophysio-
logic mechanisms of obstruction in CF bronchiectasis
include collapsible airways under conditions of high £ow
(18), airway wall thickening (19,20), plugging of small and
large airways with mucus, in£ammatory cells, and bac-
teria (20,21). Despite signi¢cant airway obstruction and
air trapping, theTLC curiously remains within the refer-
ence range even in advanced CF disease.This behavior of
theTLC is unexplained but one plausible cause is the im-
paired growth of the chest cavity due to undernutrition
associatedwith CF.
Since measurement of the DLCOSB has been widely
available in virtually all centers caring for CF patients, it
is important to de¢ne its role in the management of CF
patients. The current study found a signi¢cant positive
correlation between DLCOSB and FEV1 in adult CF, that
is, the DLCOSB decreasedwithworsening FEV1. Interest-
ingly, the mean DLCOSB fell below 80% only in the group
with severe lung impairment, consistent with the obser-
vation of Guidotti et al. (22) that the DLCO drops when
610 RESPIRATORYMEDICINE£ow rates are abnormal.We do believe that physiologic
factors that may in£uence the DLCOSB, such as anemia,
carboxyhemoglobinemia, and methemoglobinemia, did
not play a role in our CF cohort because concomitant
arterial blood gas results in14 of our 51patients failed to
show such abnormalities. Thus, a low DLCOSB may be
helpful in identifying a cohort of CF patients with ad-
vanced pulmonary diseasewhomay requiremore inten-
sive management and perhaps referral to a lung
transplant center. A prospective study on the validity of
the DLCOSB in predicting survival and need for lung
transplantationwill delineate its role in CF management.
Johnson demonstrated the volume dependence of
both di¡using capacity (DLCO) and carbon monoxide
transfer factor (KCO or DLCO/VA) and proposed equa-
tions derived by linear regression to adjust DLCO and
DLCO/VA for predicted alveolar volume (6).He tabulated
the distinctivepatterns of unadjusted and adjustedDLCO
and DLCO/VA values in various groups of patients with
lung disease.On one end, in purely restrictive extrapul-
monary respiratory conditions, the DLCO and DLCO/VA
adjusted for predicted alveolar volume tend to normalize
despite low unadjusted DLCO.On the other extreme, in
emphysema, the low DLCO and KCO remains severely
depressed when adjusted for VA% due to the loss of al-
veolar-capillary units (kDLCO) accompanying the hyper-
in£ation (mTLC or mVA) due to the decrease in speci¢c
lung elastance (23). In our cohort, the DLCOSB/VA, re-
mained elevated despite worsening lung function and
correlated poorly with measures of air£ow, hyperin£a-
tion, and air trapping. On the other hand, the DLCOSB
and DLCOSB/VAwhen adjusted for predicted alveolar vo-
lume decreasedwith and correlatedwellwithworsening
CF lung disease.This implies that, although CF primarily
causes a bronchiectatic airway disease, it subsequently
results in some degree of reduction in accessible alveolar
volume and/or alveolar capillary units. Indeed, the VA/
TLC%, a good measure of accessible alveolar volume,
dropped remarkably with worsening CF lung disease.
Pathologic ¢ndings in CF airway responsible for de-
creased alveolar access include bronchitis and muco-
purulent plugging (21). In terms of loss of alveolar
capillary units, bronchopneumonia was almost univer-
sally present among patients of all ages while emphyse-
matous involvement of the lungs also occurred in 40%
of CF patients older than 6 years, although rarely to a
severe degree (21). Nevertheless, we found that the ad-
justed DLCOSB and DLCOSB/VA values had been consis-
tently higher than the unadjusted DLCOSB and
continued to remain above 80% up until severe CF lung
disease ensued. A morphologic explanation for the rela-
tivelypreserveddi¡using capacity values inmild-to-mod-
erate CF is that there isminimal loss of alveolar capillary
units in CF since it is predominantly a disease of the air-
waysrather than theparenchyma.Aphysiologic explana-
tion proposed by Keens et al. (3) is that patients with CFproduce abnormally negative intrathoracic pressures
due to maximal inspiration against obstructed airways,
thereby increasing the pulmonary capillary blood vo-
lume. Evidence supporting the concept of increased
blood £ow to the lungs in CF includes histopathologic
studies reporting prominent arterial vessels in bronch-
iectatic airway walls (20,24) and angiographic studies de-
monstrating dilated and tortuous bronchial arteries
coupled with precapillary bronchopulmonary anasto-
moses in CF (25^28).On the contrary, published studies
using scintigraphic techniques did not seem to support
the notion of increased pulmonary blood £ow in CF and
in fact demonstratedperfusion defects predominantly in
the upper lobes (29,30). Amore plausible explanation for
the relatively preserved di¡using capacity in mild-to-
moderate CF is an enhanced ventilation^perfusion (V/
Q) relationship rather than an isolated increase in pul-
monary blood £ow. In 1968, Waring and Matta (31) de-
monstrated this improved V/Q matching by measuring
the arterial-alveolar di¡erence in nitrogen tension in 35
children with CF and adopted the term ‘‘claustration’’ to
describe a process of mucoid impaction of the bronchus
resulting in simultaneously hypoventilated andunderper-
fused alveolar-capillary units supplied by that bronchus.
A year later, Gyepes et al. (32) corroborated the im-
proved V/Q relationship in CF using scintigraphic techni-
ques, demonstrating that underventilated lung areas
were uniformly and persistently underperfused and vice
versa.Late in the course ofCF, the di¡usingcapacities fall
below normal levels when severe air£ow limitation and
extensiveparenchymal destruction fromrecurrent infec-
tions have ensued. Hence, the di¡using capacities in CF
patients are relatively preserved or increased until late
in the course of the disease due to the predominant air-
way involvement,minimal loss of alveolar-capillaryunits,
and enhanced V/Q relationship due to claustration in CF.
CONCLUSION
The unadjusted di¡using capacity for carbon monoxide
by single breath method (DLCOSB) had a signi¢cant posi-
tive correlation with measures of air£ow limitation
(FVC, FEV1/FVC,MVV%, sGaw) and negative correlation
withmeasures of air trapping (mRVandRV//TLC) in adult
CF patients and, when abnormal, can help identify those
with severe CF lung disease.TheDLCOSB/VA, when unad-
justed forVA%, remainedgreater than100% despitewor-
sening CF lung disease and did not correlate with other
measures of lung function. On the other hand, the
DLCOSB and DLCOSB/VA, when adjusted for VA%, de-
creased andwere signi¢cantlycorrelatedwithworsening
air£ow limitation and, to a lesser extent, air trapping.
The relatively preserved or increased adjusted DLCOSB
and DLCOSB/VA values in CF patients up until late in its
course may be explained the predominant airway
DIFFUSINGCAPACITYINFIBROSIS 611involvement, minimal loss of alveolar-capillary units, and
enhanced V/Q relationship due to claustration in CF.
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